1-O-[2-[2-[4-[1,3-bis[[2-[4-(1,3-dihydroxypropan-2-yloxy)-4-oxobutanoyl]oxybenzoyl]oxy]propan-2-yloxy]-4-oxobutanoyl]oxy-3-[2-[4-(1,3-dihydroxypropan-2-yloxy)-4-oxobutanoyl]oxybenzoyl]oxypropoxy]carbonylphenyl] 4-O-(1,3-dihydroxypropan-2-yl) butanedioate | 915790-50-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-O-[2-[2-[4-[1,3-bis[[2-[4-(1,3-dihydroxypropan-2-yloxy)-4-oxobutanoyl]oxybenzoyl]oxy]propan-2-yloxy]-4-oxobutanoyl]oxy-3-[2-[4-(1,3-dihydroxypropan-2-yloxy)-4-oxobutanoyl]oxybenzoyl]oxypropoxy]carbonylphenyl] 4-O-(1,3-dihydroxypropan-2-yl) butanedioate
• CAS: 915790-50-0
• 化学式: C₆₆H₇₄O₃₆
• 分子量: 1443.29
• InChiKey: YAPOPDSVHWIWDG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  102
• 可旋转键数：
  59
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  530
• 氢给体数：
  8
• 氢受体数：
  36

反应信息

• 作为反应物：
  描述：

  1-O-[2-[2-[4-[1,3-bis[[2-[4-(1,3-dihydroxypropan-2-yloxy)-4-oxobutanoyl]oxybenzoyl]oxy]propan-2-yloxy]-4-oxobutanoyl]oxy-3-[2-[4-(1,3-dihydroxypropan-2-yloxy)-4-oxobutanoyl]oxybenzoyl]oxypropoxy]carbonylphenyl] 4-O-(1,3-dihydroxypropan-2-yl) butanedioate 、 methyl (1r,4r)-4-((((benzyloxy)carbonyl)amino)methyl)cyclohexane-1-carboxylate 在 4-(dimethylamino)-pyridinium p-toluenesulfonate 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  WO2007/87256

  摘要：

  公开号：
• 作为产物：
  描述：

  4-O-[2-[2-[4-[1,3-bis[[2-[4-oxo-4-[(2-phenyl-1,3-dioxan-5-yl)oxy]butanoyl]oxybenzoyl]oxy]propan-2-yloxy]-4-oxobutanoyl]oxy-3-[2-[4-oxo-4-[(2-phenyl-1,3-dioxan-5-yl)oxy]butanoyl]oxybenzoyl]oxypropoxy]carbonylphenyl] 1-O-(2-phenyl-1,3-dioxan-5-yl) butanedioate 在 palladium over charcoal 氢气 作用下， 以 四氢呋喃 为溶剂， 生成 1-O-[2-[2-[4-[1,3-bis[[2-[4-(1,3-dihydroxypropan-2-yloxy)-4-oxobutanoyl]oxybenzoyl]oxy]propan-2-yloxy]-4-oxobutanoyl]oxy-3-[2-[4-(1,3-dihydroxypropan-2-yloxy)-4-oxobutanoyl]oxybenzoyl]oxypropoxy]carbonylphenyl] 4-O-(1,3-dihydroxypropan-2-yl) butanedioate
  参考文献：
  名称：

  WO2007/87256

  摘要：

  公开号：

文献信息

• Method of preparing dendritic drugs
  申请人：Chai Minghui

  公开号：US20070190151A1

  公开（公告）日：2007-08-16

  Synthetic design of drug-incorporated novel dendrimer structures for quantitatively controlled drug delivery. The dendritic drugs have better control and thus a quantitative drug release can be obtained. There are no prior art dendritic drugs that control release both sequentially and quantitatively like the dendritic drugs disclosed herein. The dendritic drugs are formed by incorporating multiple same type drug units or more than two different drug types into a dendritic cascade structure to form a dendrimer drug.
• METHOD OF PREPARING DENDRITIC DRUGS
  申请人：Chai Minghui

  公开号：US20160206746A1

  公开（公告）日：2016-07-21

  Synthetic design of drug-incorporated novel dendrimer structures for quantitatively controlled drug delivery. The dendritic drugs have better control and thus a quantitative drug release can be obtained. There are no prior art dendritic drugs that control release both sequentially and quantitatively like the dendritic drugs disclosed herein. The dendritic drugs are formed by incorporating multiple same type drug units or more than two different drug types into a dendritic cascade structure to form a dendrimer drug.
• US9603941B2
  申请人：——

  公开号：US9603941B2

  公开（公告）日：2017-03-28
• WO2007/87256
  申请人：——

  公开号：——

  公开（公告）日：——
• Synthesis of salicylate dendritic prodrugs
  作者：Shengzhuang Tang、Stephen M. June、Bob A. Howell、Minghui Chai

  DOI：10.1016/j.tetlet.2006.08.110

  日期：2006.10

  A small drug molecule, salicylic acid, has been converted into well-defined dendritic macromolecules. The mono-disperse nature of these materials may be clearly shown by NMR and GPC. A third generation salicylic acid dendrimer contains sixty salicylic acid residues, which make up its core, branches, and periphery. Individual salicylic acid moieties in the dendrimer are connected to one another via hydrolyzable diester linkages. (c) 2006 Elsevier Ltd. All rights reserved.